Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...

Regeneron (REGN) and Sanofi's (SNY) asthma therapy Dupixent receives FDA approval for label expansion in treating certain ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Topline results were announced from a phase 3 trial evaluating rocatinlimab for the treatment of moderate to severe atopic dermatitis.

The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary ...

Treatment for a rash on or inside the buttocks may include a combination of creams, self-care, or antivirals. Find a list of ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

Discover research presented at EADV 2024 highlighting the significant impact of atopic dermatitis on psychological and social ...

When childhood atopic dermatitis persists into adulthood, the large reduction in quality of life suggests that the price of ...

As part of the agreement to divest Caring Brands, Safety Shot will receive three million shares of Caring Brands stock. To ...

Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

Greater proportion of upadacitinib-treated patients attained near-complete skin clearance in the head and neck region.